FACE-Q Skin Cancer Module for measuring patient-reported outcomes following facial skin cancer surgery

Lee, E.H.; Klassen, Anne F.; Cano, Stefan; Nehal, Kishwer S.; Pusic, Andrea L.

doi:10.1111/bjd.16671

Cited by 75 publications

(76 citation statements)

References 42 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15,16 There is limited evidence supporting use of PROMs in NMSC populations, e.g. FACT-G, 13,16 Skin Cancer Index, 17 Facial Skin Cancer Index 18 and FACE-Q Skin Cancer Module, 19 and further evaluation of disease-specific tools is required.…”

mentioning

confidence: 99%

Use of the Skin Cancer Quality of Life Impact Tool (SCQOLIT) – a feasibility study in non‐melanoma skin cancer

Wali

Gibbons

Kelly

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background Incidence of non‐melanoma skin cancers (NMSCs) is increasing and can significantly impact on quality of life (QOL), yet there are few studies evaluating patient‐reported outcome measures (PROMs) in NMSC populations. We undertook a prospective feasibility study to evaluate a skin cancer‐specific PROM, the Skin Cancer Quality of Life Impact Tool (SCQOLIT), in patients with a new diagnosis of NMSC. Objectives (i) To establish acceptability of SCQOLIT in dermatology clinics, (ii) a descriptive analysis of SCQOLIT scores in NMSC. Methods Patients with histologically confirmed NMSC completed SCQOLIT, EQ‐5D and a transition item. Questionnaires were completed at baseline and 3 months for group 1 (‘low‐risk’ NMSC) and group 2 (‘high‐risk’ NMSC) with additional questionnaires at 6–9 months for group 2. Patients participated in structured interviews. Clinician experience was captured through staff evaluation forms and a focus group. Acceptability and psychometric properties of SCQOLIT were assessed. Results Overall, 318 patients consented to participate. Mean SCQOLIT score at baseline was 5.33, with 2.6% of patients scoring ≥20. No ceiling effects were observed, whilst 13.9% scored 0. Validity was demonstrated against EQ‐5D. Cronbach's alpha 0.84 demonstrated internal consistency. Thirteen patients were interviewed and thought SCQOLIT was comprehensive, captured impact on health‐related QOL and helped express their needs to clinicians. Most clinicians found SCQOLIT ‘very useful’ or ‘useful to some extent’ in facilitating discussions. Conclusions This feasibility study demonstrates that SCQOLIT is acceptable to patients and staff in dermatology skin cancer clinics. The psychometric properties of SCQOLIT confirm its utility in NMSC populations.

show abstract

mentioning

confidence: 99%

Use of the Skin Cancer Quality of Life Impact Tool (SCQOLIT) – a feasibility study in non‐melanoma skin cancer

Wali

Gibbons

Kelly

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…The characteristics of the included studies are summarized in Table 2. One study 20 was excluded even though it met the inclusion criteria because it was not clear whether the same women had been included in a larger study published by the same authors at a later date 21 . Therefore, only the later, larger study was included to prevent possible double counting of women.…”

Section: Resultsmentioning

confidence: 99%

“…None of these women was affected by further seizures or neurologic events. Sibai et al 20 presented the most historic data, including 223 women from a single institution between 1977 and 1989 21 . None of the women had recurrent seizures during a follow up period of 3–13 years.…”

Section: Resultsmentioning

confidence: 99%

Long‐term seizure recurrence after eclampsia: A systematic review and meta‐analysis

Barber

Dobbs

Gibson

et al. 2020

Intl J Gynecology & Obste

View full text Add to dashboard Cite

Background: Seizure recurrence after a fit has implications for both individuals and healthcare providers guiding neurologic prognosis, treatment, and driving and work restrictions. A systematic review of long-term seizure recurrence after eclampsia will help to quantify recurrence risk in this setting. Objective: To evaluate the long-term recurrence of seizures after eclampsia. Search strategy: After PROSPERO registration, Medline (Ovid), Embase, and Cochrane Library were searched by using the terms (eclampsia OR eclamp* OR eclamptic seizure* OR eclamptic fit*) AND (recur* OR recurrent fit* OR recurrent seizure*) for studies published up until December 2019. Selection criteria: Studies describing long-term seizure recurrence after a diagnosis of eclampsia were included. Data collection and analysis: Data were extracted from studies independently by two authors. Pooled prevalence was calculated and weighted based on sample size with a 95% confidence interval (CI). Main results: Initially, 1754 unique studies were identified and 4 were included in the final analysis. The studies involved 1896 women, of whom 7 (0.37%) were affected by a further seizure. The weighted pooled prevalence of seizure recurrence was 0.18% (95% CI, 0.03-1.02). Conclusion: The absolute rate of long-term seizure recurrence after eclampsia is extremely low and within safe limits for driving.

show abstract

“…The FACE-Q is a validated, patient-reported outcome instrument used to quantify health-related quality of life after facial surgery. 5 The Skin Cancer Module within the FACE-Q evaluates variables related to facial skin cancers. The purpose of this study was to measure patient-reported outcomes and identify factors associated with patient satisfaction after excision of facial nonmelanoma skin cancer in the veteran population.…”

Section: Patient-reported Outcomes and Factors Associated With Patienmentioning

confidence: 99%

Patient-Reported Outcomes and Factors Associated With Patient Satisfaction After Surgical Treatment of Facial Nonmelanoma Skin Cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

FACE-Q Skin Cancer Module for measuring patient-reported outcomes following facial skin cancer surgery

Abstract: The FACE-Q Skin Cancer Module meet the requirements of the Rasch model providing linearized measurement. Discriminating between patients with minimal appearance or worry impairment may be a limitation. The scales can be used for larger validation studies, clinical practice and research.

Cited by 75 publications

References 42 publications

Use of the Skin Cancer Quality of Life Impact Tool (SCQOLIT) – a feasibility study in non‐melanoma skin cancer

Use of the Skin Cancer Quality of Life Impact Tool (SCQOLIT) – a feasibility study in non‐melanoma skin cancer

Long‐term seizure recurrence after eclampsia: A systematic review and meta‐analysis

Patient-Reported Outcomes and Factors Associated With Patient Satisfaction After Surgical Treatment of Facial Nonmelanoma Skin Cancer

Contact Info

Product

Resources

About